Portal de Periódicos da CAPES

The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer

2016; Impact Journals LLC; Volume: 8; Issue: 3 Linguagem: Inglês

10.18632/oncotarget.14125

1949-2553

Chenchen Wei, Fengqi Nie, Lili Jiang, Qinnan Chen, Zhenyao Chen, Xin Chen, Xuan Pan, Zhili Liu, Binbin Lu, Zhao-xia Wang,

Epigenetics and DNA Methylation

// Chen-Chen Wei 1, * , Feng-Qi Nie 1, * , Li-Li Jiang 1, 2, * , Qin-Nan Chen 1 , Zhen-Yao Chen 1 , Xin Chen 1 , Xuan Pan 3 , Zhi-Li Liu 4 , Bin-Bin Lu 1 , Zhao-Xia Wang 1 1 Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China 2 Department of Oncology, Haimen People's Hospital, Haimen, People's Republic of China 3 Department of Medical Oncology, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Cancer Institution of Jiangsu Province, Nanjing, People's Republic of China 4 Department of Oncology, The Affiliated Jiangyin Hospital, School of Medicine, Southeast University, Jiangyin, People's Republic of China * These authors contributed equally to this work and should be regarded as joint first authors Correspondence to: Zhao-Xia Wang, email: zhaoxiawang88@126.com Keywords: pseudogene, DUXAP10, LSD1, proliferation, migration and invasion Received: June 06, 2016 Accepted: November 21, 2016 Published: December 23, 2016 ABSTRACT Pseudogenes have been considered as non-functional transcriptional relics of human genomic for long time. However, recent studies revealed that they play a plethora of roles in diverse physiological and pathological processes, especially in cancer, and many pseudogenes are transcribed into long noncoding RNAs and emerging as a novel class of lncRNAs. However, the biological roles and underlying mechanism of pseudogenes in the pathogenesis of non small cell lung cancer are still incompletely elucidated. This study identifies a putative oncogenic pseudogene DUXAP10 in NSCLC, which is located in 14q11.2 and 2398 nt in length. Firstly, we found that DUXAP10 was significantly up-regulated in 93 human NSCLC tissues and cell lines, and increased DUXAP10 was associated with patients poorer prognosis and short survival time. Furthermore, the loss and gain of functional studies including growth curves, migration, invasion assays and in vivo studies verify the oncogenic roles of DUXAP10 in NSCLC. Finally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells. Taken together, these findings demonstrate DUXAP10 exerts the oncogenic roles through binding with LSD1 and epigenetic silencing LATS2 and RRAD expression. Our investigation reveals the novel roles of pseudogene in NSCLC, which may serve as new target for NSCLC diagnosis and therapy.